Answers are grounded in this paper and cite their sources.
The use of DTG+backbone may be cost effective in treatment-naïve and treatment-experienced patients compared with RAL+backbone and in treatment-naïve patients compared with DRV/r+backbone and EFV/TDF/FTC considering a threshold of 40,000 €/QALY.
No takes yet. Share an insight, caveat, or question.
Restelli et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: